Cost-effectiveness and value of information analyses of Bruton’s tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States

BACKGROUND: Ibrutinib, acalabrutinib, and zanubrutinib have shown improvements in efficacy and safety over conventional chemoimmunotherapy in refractory or relapsed mantle cell lymphoma (R/R MCL). OBJECTIVE: To evaluate the comparative cost-effectiveness of the Bruton’s tyrosine kinase inhibitors (B...

Descripción completa

Detalles Bibliográficos
Autores principales: Alrawashdh, Neda, McBride, Ali, Slack, Marion, Persky, Daniel, Andritsos, Leslie, Abraham, Ivo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372983/
https://www.ncbi.nlm.nih.gov/pubmed/35332792
http://dx.doi.org/10.18553/jmcp.2022.28.4.390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372983/
https://www.ncbi.nlm.nih.gov/pubmed/35332792
http://dx.doi.org/10.18553/jmcp.2022.28.4.390

Ejemplares similares